EUVIMEDEUVIMED entdecken
Crossref

Patient-reported burden associated with pheochromocytoma/paraganglioma diagnosis

Katherine I Wolf, Linda Rose-Krasnor, Stephanie Alband, Jacques W M Lenders, Lauren Fishbein iD

Endocrine-Related Cancer · 2024

DOI: 10.1530/erc-23-0349 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Endocrine-Related Cancer, 2024. Verfasst von Katherine I Wolf und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Metabolism, Endocrinology and Diabetes, University of Michigan, Ann Arbor, Michigan, USA. Hauptthemen laut MEDLINE: Pheochromocytoma, Adrenal Gland Neoplasms, Paraganglioma. Die Arbeit nennt 26 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pheochromocytoma and paragangliomas (PPGLs) originate from the chromaffin cells of the adrenal medulla or neural crest progenitors outside the adrenal gland, respectively. The estimated annual incidence of PPGL is between 2.0 and 8.0/million adults. Minimal data exist on the impact of PPGL from the patient’s perspective. Therefore, a survey was adapted from a previously published study on gastroenteropancreatic neuroendocrine tumors to explore the voice of patients with PPGL and learn ways to improve clinical care while understanding the current gaps to direct future research. A self-reported online survey was available to patients with PPGL and those with genetic predisposition even without PPGL from June to July 2022. Survey questions captured sociodemographic and clinical characteristics, the diagnostic workup, treatment and monitoring, quality and access to care, and financial impact. Here, we report the most relevant findings on patient experience of disease burden following diagnosis. A total of 270 people responded, the majority of whom were from the USA (79%), Caucasian (88%), and female (81%). The results of this survey highlight the burden of disease on a patient’s daily life, resulting in moderate to severe financial distress, increased travel time to specialized facilities resulting in loss of work and wages, and significant delays in care. Respondents reported being unheard and unacknowledged. With a median time to diagnosis just over 2 years, the physical, mental, and emotional toll are substantial. Increasing access to PPGL specialists and centers could lead to faster diagnoses and better management, which may reduce the burden on both patients and healthcare centers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PheochromocytomaAdrenal Gland NeoplasmsParagangliomaHumansFemaleMaleAdultMiddle AgedAgedCost of IllnessYoung AdultAdolescentPatient Reported Outcome MeasuresSurveys and Questionnaires

Stichwörter der Autor:innen

paragangliomapatient engagementpatient-centered carepheochromocytoma

Autor:innen und Institutionen

  • Department of Medicine, Division of Metabolism, Endocrinology and Diabetes, University of Michigan, Ann Arbor, Michigan, USA.
  • Pheo Para Alliance and Psychology Department, Brock University, St. Catharines, Ontario, Canada.
  • Pheo Para Alliance, Alexandria, Virginia, USA.
  • Department of Internal Medicine, Radboud University Medical Centre, Nijmegen, The Netherlands.
  • Department of Medicine, Division of Endocrinology, Metabolism and Diabetes, and Department of Biomedical Informatics, University of Colorado School of Medicine, Aurora, Colorado, USA.

ORCID-Profile: Lauren Fishbein

Zitieren

APA

Wolf, K. I., Rose-Krasnor, L., Alband, S., Lenders, J. W. M., & Fishbein, L. (2024). Patient-reported burden associated with pheochromocytoma/paraganglioma diagnosis. Endocrine-Related Cancer. https://doi.org/10.1530/erc-23-0349

Vancouver

Wolf KI, Rose-Krasnor L, Alband S, Lenders JWM, Fishbein L. Patient-reported burden associated with pheochromocytoma/paraganglioma diagnosis. Endocrine-Related Cancer. 2024. doi:10.1530/erc-23-0349

BibTeX
@article{Wolf2024,
  author = {Wolf, Katherine I and Rose-Krasnor, Linda and Alband, Stephanie and Lenders, Jacques W M and Fishbein, Lauren},
  title = {Patient-reported burden associated with pheochromocytoma/paraganglioma diagnosis},
  journal = {Endocrine-Related Cancer},
  year = {2024},
  doi = {10.1530/erc-23-0349}
}
Kostenlos starten →